New hope for tough breast cancer: targeted drug trial opens

NCT ID NCT06908928

First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 27 times

Summary

This early-phase trial tests a new drug called bulumtatug furvedotin (BFv) in people with triple-negative breast cancer that has returned or spread and who have already tried certain other treatments. The study aims to see if BFv can shrink tumors or stop them from growing. About 52 participants will receive the drug, and researchers will monitor how well it works and any side effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TRIPLE NEGATIVE BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Email: •••••@•••••

Locations

  • Anschutz Medical Center

    RECRUITING

    Aurora, Colorado, 80045, United States

  • City of Hope

    RECRUITING

    Duarte, California, 91010, United States

    Contact Phone: •••-•••-••••

    Contact

  • Massachusetts General Hospital

    RECRUITING

    Boston, Massachusetts, 02114, United States

  • Memorial Sloan Kettering Cancer Center

    RECRUITING

    New York, New York, 10021, United States

    Contact Phone: •••-•••-••••

    Contact

  • UCSD Moores Cancer Center

    RECRUITING

    La Jolla, California, 92093, United States

    Contact Phone: •••-•••-••••

    Contact

  • UChicago Medicine Comprehensive Cancer Center

    RECRUITING

    Chicago, Illinois, 60637, United States

    Contact Phone: •••-•••-••••

    Contact

Conditions

Explore the condition pages connected to this study.